Explore the latest groundbreaking treatment approaches for early-stage triple-negative breast cancer (TNBC) in this engaging tumor board! The multidisciplinary panel of expert faculty will dive into a case involving a patient with early TNBC and discuss the latest data and potential roles of PARP inhibitors (PARPIs) in the first CME activity offered in this TNBC series.
Claim credit: https://www.achlcme.org/PARPis-tnbc-onctube
Access the three-part series: https://www.achlcme.org/triple-negative-breast-cancer
Advertisement